Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$18.31 -2.9%	$15.87	$9.57 ▼ $30.41	$2.60B	0.93	1.56 million shs	1.45 million shs
FGEN FibroGen	$7.15 -2.7%	$6.97	$4.50 ▼ $38.25	$29.71M	0.74	76,113 shs	59,782 shs
GWPH GW Pharmaceuticals	$218.96	$218.59	$87.07 ▼ $219.57	$6.86B	2.15	899,771 shs	N/A
MRTX Mirati Therapeutics	$58.70	$58.82	$27.30 ▼ $64.41	$4.12B	0.77	2.76 million shs	N/A
NKTR Nektar Therapeutics	$25.01 -0.4%	$14.22	$6.48 ▼ $37.38	$311.42M	0.94	502,718 shs	1.21 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-2.92%	+9.12%	+9.38%	+55.30%	-31.73%
FGEN FibroGen	-2.72%	+25.66%	-7.44%	+3.17%	-68.34%
GWPH GW Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
MRTX Mirati Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
NKTR Nektar Therapeutics	-0.36%	+1.46%	+161.88%	+169.93%	+25.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.5858 of 5 stars	3.4	2.0	0.0	3.4	2.1	1.7	0.0
FGEN FibroGen	4.7256 of 5 stars	3.3	4.0	0.0	4.7	3.8	3.3	0.6
GWPH GW Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRTX Mirati Therapeutics	0.4379 of 5 stars	0.0	0.0	0.0	4.7	0.6	0.0	0.6
NKTR Nektar Therapeutics	4.0975 of 5 stars	3.4	2.0	0.0	4.2	3.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	138.75% Upside
FGEN FibroGen	2.50	Moderate Buy	$250.00	3,396.50% Upside
GWPH GW Pharmaceuticals	0.00	N/A	N/A	N/A
MRTX Mirati Therapeutics	0.00	N/A	N/A	N/A
NKTR Nektar Therapeutics	2.86	Moderate Buy	$88.33	253.19% Upside

Current Analyst Ratings Breakdown

Latest GWPH, FGEN, ARWR, NKTR, and MRTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	NKTR Nektar Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $85.00
6/24/2025	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$60.00 ➝ $100.00
6/24/2025	NKTR Nektar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$120.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/13/2025	FGEN FibroGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$250.00 ➝ $250.00
5/12/2025	NKTR Nektar Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	712.28	N/A	N/A	$1.54 per share	11.89
FGEN FibroGen	$29.62M	0.98	N/A	N/A	($50.89) per share	-0.14
GWPH GW Pharmaceuticals	$311.33M	22.05	$0.01 per share	18,588.22	$23.48 per share	9.33
MRTX Mirati Therapeutics	$12.44M	331.01	N/A	N/A	$17.31 per share	3.39
NKTR Nektar Therapeutics	$98.43M	3.15	N/A	N/A	$4.94 per share	5.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	22.18	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
FGEN FibroGen	-$47.58M	-$2.50	N/A	N/A	N/A	-9.73%	N/A	-24.77%	8/5/2025 (Estimated)
GWPH GW Pharmaceuticals	-$9.02M	-$0.24	N/A	608.22	N/A	-11.05%	-7.46%	-6.13%	N/A
MRTX Mirati Therapeutics	-$740.87M	-$12.22	N/A	N/A	N/A	-1,900.65%	-82.15%	-67.82%	N/A
NKTR Nektar Therapeutics	-$118.96M	-$9.60	N/A	N/A	N/A	-152.49%	-329.54%	-55.24%	8/6/2025 (Estimated)

Latest GWPH, FGEN, ARWR, NKTR, and MRTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	FGEN FibroGen	-$0.09	N/A	N/A	N/A	$2.88 million	N/A
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/12/2025	Q1 2025	FGEN FibroGen	$0.75	-$4.00	-$4.75	$0.05	$2.00 million	$2.70 million
5/8/2025	Q1 2025	NKTR Nektar Therapeutics	-$2.70	-$3.30	-$0.60	-$0.24	$15.61 million	$10.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
GWPH GW Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRTX Mirati Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
FGEN FibroGen	N/A	2.02	1.98
GWPH GW Pharmaceuticals	0.01	5.13	4.31
MRTX Mirati Therapeutics	N/A	7.54	7.40
NKTR Nektar Therapeutics	N/A	3.24	3.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
FGEN FibroGen	72.71%
GWPH GW Pharmaceuticals	81.00%
MRTX Mirati Therapeutics	N/A
NKTR Nektar Therapeutics	75.88%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
FGEN FibroGen	3.07%
GWPH GW Pharmaceuticals	3.10%
MRTX Mirati Therapeutics	3.26%
NKTR Nektar Therapeutics	5.25%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
FGEN FibroGen	570	4.04 million	3.92 million	Optionable
GWPH GW Pharmaceuticals	1,161	31.35 million	N/A	Optionable
MRTX Mirati Therapeutics	587	70.15 million	67.86 million	Optionable
NKTR Nektar Therapeutics	220	12.41 million	11.76 million	Optionable

GWPH, FGEN, ARWR, NKTR, and MRTX Headlines

Recent News About These Companies

Wealth Enhancement Advisory Services LLC Purchases New Shares in Nektar Therapeutics (NASDAQ:NKTR)

4 hours ago | marketbeat.com

Q2 EPS Forecast for Nektar Therapeutics Lowered by Analyst

5 hours ago | americanbankingnews.com

Nektar Therapeutics (NASDAQ:NKTR) Receives $84.17 Consensus PT from Analysts

July 11 at 2:54 AM | americanbankingnews.com

Q2 EPS Estimate for Nektar Therapeutics Reduced by Analyst

July 10 at 8:17 AM | marketbeat.com

Nektar Therapeutics (NASDAQ:NKTR) Shares Sold by Peapod Lane Capital LLC

July 10 at 7:26 AM | marketbeat.com

49 Wealth Management LLC Buys New Holdings in Nektar Therapeutics (NASDAQ:NKTR)

July 9 at 6:45 AM | marketbeat.com

Nektar Therapeutics (NASDAQ:NKTR) Given New $85.00 Price Target at B. Riley

July 9 at 3:58 AM | americanbankingnews.com

B. Riley Raises Nektar Therapeutics (NASDAQ:NKTR) Price Target to $85.00

July 8, 2025 | marketbeat.com

Nektar Therapeutics (NASDAQ:NKTR) Receives Consensus Rating of "Buy" from Brokerages

July 8, 2025 | marketbeat.com

Nektar Therapeutics Reports Positive Phase 2b Results for Eczema Treatment Rezpegaldesleukin

July 6, 2025 | msn.com

Why Nektar Therapeutics Stock Dived by 3% Today

July 3, 2025 | fool.com

What is Zacks Research's Estimate for NKTR FY2025 Earnings?

July 3, 2025 | marketbeat.com

Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

July 2, 2025 | prnewswire.com

Q2 EPS Estimate for Nektar Therapeutics Lowered by Analyst

July 2, 2025 | marketbeat.com

Nektar Therapeutics Announces Public Offering of Shares

July 1, 2025 | tipranks.com

Nektar Therapeutics stock dips after pricing $100M stock offering

July 1, 2025 | seekingalpha.com

Nektar Therapeutics Announces Pricing of $100 Million Public Offering

July 1, 2025 | prnewswire.com

Nektar Therapeutics launches proposed public offering

June 30, 2025 | msn.com

Nektar Therapeutics stock falls after announcing public offering

June 30, 2025 | in.investing.com

Nektar Therapeutics Announces Proposed Public Offering

June 30, 2025 | prnewswire.com

Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

...

June 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
By Nathan Reiff | June 30, 2025
View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
By Leo Miller | June 28, 2025
View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

GWPH, FGEN, ARWR, NKTR, and MRTX Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$18.31 -0.55 (-2.92%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$18.27 -0.04 (-0.22%)

As of 07/11/2025 07:54 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

FibroGen NASDAQ:FGEN

$7.15 -0.20 (-2.72%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$7.30 +0.15 (+2.10%)

As of 07/11/2025 07:00 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

GW Pharmaceuticals NASDAQ:GWPH

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Mirati Therapeutics NASDAQ:MRTX

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Nektar Therapeutics NASDAQ:NKTR

$25.01 -0.09 (-0.36%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$24.74 -0.28 (-1.10%)

As of 07/11/2025 07:56 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time